Epidiolex

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and its subsidiary, GW Pharmaceuticals have begun construction of its new, state-of-the-art manufacturing facility at Kent Science Park (KSP) in Sittingbourne, UK, with an investment of over $100 million.  The new facility, expected to be...

The U.S. District Court for the Western District of Texas dismissed a lawsuit filed by Canadian cannabis giant Canopy Growth (NASDAQ: CGC) against GW Pharmaceuticals on Feb. 25th. The lawsuit was initially filed in 2020, and since then, Britain’s GW Pharma was...

Jazz Pharmaceuticals plc (NASDAQ: JAZZ), a global biopharmaceutical company and manufacturer of Epidolex, announced its financial results late Tuesday for the full year and fourth quarter of 2021 and provided financial guidance for 2022. "2021 was a transformative year for Jazz,...

Biopharmaceutical company Jazz Pharmaceuticals plc (NASDAQ: JAZZ) reported its financial results on Tuesday for the second quarter of 2021 with total revenue of $751.81 million, up by 34% from $562.43 million in the comparative period of 2020. Financial...

Cannabis operators and executives tell Benzinga that the movement of private and public companies may serve as a better indicator of regulatory activity than the federal government. At the very least, they say that the industry has made advancements so far without the efforts of Capitol Hill....

The biopharmaceutical company Jazz Pharmaceuticals (NASDAQ: JAZZ), has finalized the acquisition of the cannabinoid drug company GW Pharmaceuticals plc. (NASDAQ: GWPH). The transaction, previously announced in February, was recently approved by GW Pharmaceuticals shareholders. The Jazz-GW...

Neptune Revenue Declines 63% YoY, Shifts To CPG And Branded Products Global health and wellness company Neptune Wellness Solutions Inc. (NASDAQ: NEPT) (TSX: NEPT) revealed Monday its third-quarter financial results, on the heels of announcing the purchase of a 50.1% stake in baby food and...

Canadian cannabis giant Canopy Growth Corp (NYSE: CGC) filed an federal lawsuit last week against Britain’s GW Pharma (NASDAQ: GWPH). In the lawsuit filed in the U.S. District Court for the Western District of Texas, Canopy accuses GW Pharma of unauthorized usage of Canopy’s...

GW Pharmaceuticals plc (NASDAQ: GWPH) said Monday that the results of the company’s positive Phase 3 clinical trial of Epidiolex oral solution in seizures related to tuberous sclerosis complex were published in JAMA Neurology.   Epidiolex is the first FDA-authorized CBD medicine for...

Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session. On any given...

Biopharmaceutical company GW Pharmaceuticals plc (NASDAQ: GWPH) revealed Tuesday that its revenue for the third quarter hit $137.1 million, up by 51% year-over-year. For the first nine months of this fiscal year, total revenue amounted to $378.6 million versus $202.3 million for the...

GW Pharmaceuticals plc (NASDAQ: GWPH) confirmed Monday it has obtained a notice from the Drug Enforcement Administration certifying that its Epidiolex oral solution has been descheduled and is no longer a controlled substance. “This notification from DEA fully establishes that EPIDIOLEX...

A drug from GW Pharmaceuticals plc (NASDAQ: GWPH) targeting a cause of genetic epilepsy has received Priority Review status from the U.S. Food and Drug Administration.  The Cambridge, U.K.-based company and its subsidiary Greenwich Biosciences Inc. confirmed Tuesday...

GW Pharmaceuticals plc (NASDAQ: GWPH) said Friday it has submitted a Type II Variation Application to the European Medicines Agency, applying for authorization of its Epidyolex — Epidiolex in the U.S. — cannabidiol oral solution for the management of seizures related to tuberous...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) shares are retreating following the release of fourth-quarter results. GW Pharmaceuticals reported quarterly losses of 7 cents per share, which beat the consensus estimate by 68 cents . This is a 65% increase over losses of 20 cents per share from the same...